-
[show abstract]
[hide abstract]
ABSTRACT: Elevation of intracellular Ca²⁺ in T-lymphocytes as a consequence of T cell antigen receptor activation triggers transcriptional programs resulting in effector cytokine secretion and immune response coordination. Increase of Ca²⁺ concentration in T-lymphocytes follows both the Ins(1,4,5)P(3)-dependent release from an intracellular store and subsequent influx from extracellular milieu. Flow cytometry and the fluorescent dye Fluo-4AM have been used to demonstrate that noncompetitive NMDA receptor antagonist (+)-MK801 inhibits Ca²⁺ influx in T cells induced by thapsigargin. Combination of thapsigargin and (+)-MK801 with following incubation does not affect Ca²⁺ mobilization from intracellular stores, while decreased Ca²⁺ entry was observed. Overall data indicate that the ion channel blocker (+)-MK801 is able to inhibit the Ca²⁺ influx and confirm our suggestion about involvement of NMDA receptor in the store-operated Ca²⁺ entry mechanisms in human T-lymphocytes. To identify the signal transduction pathways associated with NMDA receptors in mitogen-stimulated T-lymphocytes, the cells were incubated with (+)-MK801, then activity of key phosphorylated protein kinases of MAP-activated (pERK1/2, pSAPK/JNK, p-p38), Ca²⁺-dependent (pCaMKII), PI3/Akt-dependent (pGSK-3β), and PKC-activated (pPKCθ) pathways were detected. The data we obtained demonstrate that (+)-MK801 treatment leads to more prominent decrease in Ras-activated protein kinases pERK1/2 and Rac-activated proteins p-p38 and pSAPK/JNK, as compared to DAG-dependent pPKCθ and Ca²⁺-dependent pCaMKII. These results show that NMDA receptors are mainly involved in regulation of Ras/Rac-dependent signaling in T-lymphocytes.
Biochemistry (Moscow) 11/2011; 76(11):1220-6. · 1.06 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The Atlas Rat cDNA Expression Array (BD Biosciences, United States) has been used to analyze changes in the expression of 588 genes in rat brain cells in response to a single administration of Ladasten, a 2-aminoadamantane derivative that has psychostimulating and anxiolytic effects. The analysis of hybridization on macroarrays, confirmed by the results of real-time quantitative RT-PCR, has demonstrated that Ladasten alters the expression of 12 genes in the rat brain. The GAT3 and CARBH genes are presumed to be pharmacologically important targets of Ladasten. The changes in their activity explain the mechanisms of the anxiolytic and mood-stabilizing effects of the drug. Ladasten has been shown to induce the genes whose products are involved in various signal pathways (APC, Rb, PKCIP, and PMCA), as well as the genes of cytoskeletal proteins (Tub1 and actin), synaptic proteins (SynIA&IB and PLP), and enzymes (Gapdh and NSE). The proteins encoded by these genes are presumably involved in compensatory and/or neuroplastic adaptation to the effects of Ladasten.
Molecular Biology 02/2005; 39(2):244-252. · 0.66 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: We have used the Rat Atlas cDNA Array ("BD Bioscience") to assess changes in mRNA expression of 588 genes in rat brain after acute treatment of 2-aminoadamantane compound--Ladasten. Drug exhibits the psychostimulating and anxyolitic actions. The analysis of results of hybridization on macrochips and their corroboration by quantitative real-time RT-PCR has allowed to reveal 12 genes, expression of which changes in response to ladasten in rat brain cells. The GAT3 and CARBH genes should be considered as primary pharmacologically significant targets and the changes of their functional conditions allows to explain the distinct mechanisms of anxyolitic properties of the drug. It was shown that Ladasten induced genes are involved in the different signalling pathways (APC, Rb, PKCIP, PMCA), genes encoding the cytosceletal proteins (Tubal, actin), synaptic proteins (Syn IA&IB, PLP) and metabolism enzymes (Gapdh, NSE). It is possible to assume, that proteins, encoded by the given genes participate in the compensatory and/or neuroplastic adaptation to biochemical effects of Ladasten.
Molekuliarnaia biologiia 39(2):276-85.
-
Eksperimental'naia i klinicheskaia farmakologiia 64(3):3-12.
-
Doklady Biochemistry and Biophysics 401:150-3. · 0.33 Impact Factor
